24.10

3.83% -0.96

After Hours: 24.39 0.29 +1.20%

Ultragenyx Pharmaceutical Inc (RARE)

Overview News Price History Option Chain Financials Why RARE Down? Discussions Forecast Stock Split

Ultragenyx Pharmaceutical Inc stock is traded at $24.10, with a volume of 1.39M. It is down -3.83% in the last 24 hours and up +21.29% over the past month. Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Previous Close:

$25.06

Open:

$25.17

24h Volume:

1.39M

Relative Volume:

0.65

Market Cap:

$2.37B

Revenue:

$672.72M

Net Income/Loss:

$-575.44M

P/E Ratio:

-4.1295

EPS:

-5.8361

Net Cash Flow:

$-487.00M

1W Performance:

-1.91%

1M Performance:

+21.29%

6M Performance:

-29.51%

1Y Performance:

-31.92%

1-Day Range:

$23.95

$25.21

1-Week Range:

$23.95

$26.19

52-Week Range:

$18.29

$42.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name

Ultragenyx Pharmaceutical Inc

Sector

Healthcare (1113)

Industry

Biotechnology (624)

Phone

415-483-8800

Address

60 LEVERONI COURT, NOVATO, CA

Employee

1,371

Twitter

Next Earnings Date

2026-05-05

Latest SEC Filings

RARE's Discussions on Twitter

Compare RARE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RARE Ultragenyx Pharmaceutical Inc	24.10	2.46B	672.72M	-575.44M	-487.00M	-5.8361
VRTX Vertex Pharmaceuticals Inc	436.59	111.71B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	747.36	79.23B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	805.38	51.89B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	308.43	41.49B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	312.31	35.31B	5.36B	287.73M	924.18M	2.5229

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Downgrade	Goldman	Buy → Neutral
Oct-20-25	Initiated	Wells Fargo	Overweight
Jul-28-25	Resumed	H.C. Wainwright	Buy
May-28-25	Initiated	William Blair	Outperform
Jun-06-24	Upgrade	Goldman	Neutral → Buy
Apr-22-24	Initiated	RBC Capital Mkts	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight
Jun-14-23	Resumed	Credit Suisse	Outperform
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight
Jan-18-23	Resumed	Canaccord Genuity	Buy
Dec-30-22	Resumed	H.C. Wainwright	Buy
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight
Sep-30-21	Initiated	H.C. Wainwright	Buy
Aug-19-21	Initiated	UBS	Sell
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
May-06-21	Upgrade	Citigroup	Neutral → Buy
May-06-21	Upgrade	Evercore ISI	In-line → Outperform
Apr-26-21	Resumed	Credit Suisse	Neutral
Mar-02-21	Resumed	Stifel	Buy
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-07-20	Downgrade	Wedbush	Outperform → Neutral
Nov-24-20	Resumed	Evercore ISI	In-line
Nov-12-20	Downgrade	BofA Securities	Buy → Neutral
Aug-02-19	Resumed	Wedbush	Outperform
Mar-27-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Feb-22-19	Resumed	Raymond James	Outperform
Jan-02-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-08-18	Upgrade	Citigroup	Sell → Neutral
Sep-10-18	Initiated	Morgan Stanley	Equal-Weight
Jun-21-18	Downgrade	Credit Suisse	Outperform → Neutral
May-11-18	Upgrade	Barclays	Equal Weight → Overweight
May-10-18	Initiated	Goldman	Neutral
Apr-18-18	Upgrade	SunTrust	Hold → Buy
Mar-22-18	Resumed	Piper Jaffray	Overweight
Feb-21-18	Reiterated	Stifel	Buy
Jan-22-18	Upgrade	Evercore ISI	In-line → Outperform
Jan-18-18	Initiated	Credit Suisse	Outperform
Dec-05-17	Reiterated	Barclays	Equal Weight
Dec-04-17	Upgrade	Jefferies	Hold → Buy
Sep-14-17	Upgrade	Wedbush	Neutral → Outperform

View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

Apr 20, 2026

Ultragenyx (RARE) CEO gets new RSUs, options and shifts 400K shares - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) awards RSUs and 79,936 stock options to officer - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) awards RSUs and stock options to executive Pinion - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) grants EVP 28,895 RSUs and 49,960 options - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) EVP Harris receives RSU and option grants in equity award - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) CMO receives 34,674 RSUs and 59,952 stock options - Stock Titan

Apr 20, 2026

Ultragenyx (RARE) CFO granted 34,674 RSUs and 59,952 options in equity awards - Stock Titan

Apr 20, 2026

Ultragenyx Pharmaceutical stock (US74930A1043): Does its rare disease focus deliver the growth U.S. - AD HOC NEWS

Apr 20, 2026

Apr 17, 2026

Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo

Apr 17, 2026

Osteogenesis Imperfecta Market to Expand Significantly by 2034 with Advancements in Novel Therapies and Rising Disease Awareness, Reports DelveInsight - Barchart.com

Apr 17, 2026

Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com

Apr 17, 2026

Massachusetts Financial Services Co. MA Has $7.13 Million Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Apr 17, 2026

Apr 16, 2026

Free cash flow per share of Ultragenyx Pharmaceutical, Inc. – BIVA:RARE - TradingView — Track All Markets

Apr 16, 2026

RARE Maintained by Morgan Stanley -- Price Target Raised to $67 - GuruFocus

Apr 16, 2026

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says - MarketBeat

Apr 16, 2026

Apr 13, 2026

Bear Alert: What are the future prospects of Ultragenyx Pharmaceutical IncWeekly Earnings Recap & Safe Capital Growth Tips - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Ultragenyx downgraded to neutral at Goldman Sachs on setrusumab data - MSN

Apr 12, 2026

Ultragenyx Pharmaceutical: The Market Is Overlooking 2026 Catalysts (NASDAQ:RARE) - Seeking Alpha

Apr 12, 2026

Apr 11, 2026